Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Shital Patel

HIV/AIDS Medicine · BCM

View

Dr. Monica Gandhi

HIV/AIDS Medicine · UCSF

View

Dr. Ashwin Balagopal

HIV/AIDS Medicine · Johns Hopkins

View

Dr. Ofole Mgbako

HIV/AIDS Medicine · NYU Langone

View

Dr. Joshua Barocas

HIV/AIDS Medicine · CU Anschutz Medical Campus

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Keith Kaye

General ID · RU

View

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges

    May 14, 2026DOI: 10.1056/nejmc2604136CorrespondenceNEJM

    Summary

    To the Editor: Recently, Rana et al. published the results of the LATITUDE trial, which involved a population of patients with challenges in adhering to antiretroviral treatment. The results are very encouraging for the future of injectable treatment in this population. The authors state that standard care was a regimen of three or more drugs that included an integrase strand-transfer inhibitor (INSTI), protease inhibitor, or both; however, given that efficacy and side effects differ among regimens, it would be interesting to know which specific antiretroviral regimens served as the comparator for the injectable treatment. Furthermore, 120 patients were excluded from . . .
    RLDr. Raphael J. Landovitz
    Leading Voice

    Dr. Raphael J. Landovitz

    Infectious Disease · HIV & AIDS Medicine
    University of California, Los Angeles
    raphaell
    Los Angeles, CA, USA